In a promising development for diabetes treatment, researchers have developed a network of nanoscale particles that can be injected into the body and release insulin when blood-sugar levels rise, maintaining normal blood sugar levels for more than a week in animal-based laboratory tests.
“We’ve created a ‘smart’ system that is injected into the body and responds to changes in blood sugar by releasing insulin, effectively controlling blood-sugar levels,” says Dr. Zhen Gu, lead author of a paper describing the work and an assistant professor in the joint biomedical engineering program at NC State and UNC Chapel Hill. “We’ve tested the technology in mice, and one injection was able to maintain blood sugar levels in the normal range for up to 10 days.”
When a patient has type 1 diabetes, his or her body does not produce sufficient insulin, a hormone that transports glucose – or blood sugar – from the bloodstream into the body’s cells. This can cause a host of health effects. Currently, diabetes patients must take frequent blood samples to monitor their blood-sugar levels and inject insulin as needed to ensure their blood sugar levels are in the “normal” range. However, these injections can be painful, and it can be difficult to determine the accurate dose level of insulin. Administering too much or too little insulin poses its own health risks.
The new, injectable nano-network is composed of a mixture containing nanoparticles with a solid core of insulin, modified dextran and glucose oxidase enzymes. When the enzymes are exposed to high glucose levels they effectively convert glucose into gluconic acid, which breaks down the modified dextran and releases the insulin. The insulin then brings the glucose levels under control. The gluconic acid and dextran are fully biocompatible and dissolve in the body.
Each of these nanoparticle cores is given either a positively charged or negatively charged biocompatible coating. The positively charged coatings are made of chitosan (a material normally found in shrimp shells), while the negatively charged coatings are made of alginate (a material normally found in seaweed).
When the solution of coated nanoparticles is mixed together, the positively and negatively charged coatings are attracted to each other to form a “nano-network.” Once injected into the subcutaneous layer of the skin, the nano-network holds the nanoparticles together and prevents them from dispersing throughout the body. Both the nano-network and the coatings are porous, allowing blood – and blood sugar – to reach the nanoparticle cores.
“This technology effectively creates a ‘closed-loop’ system that mimics the activity of the pancreas in a healthy person, releasing insulin in response to glucose level changes,” Gu says. “This has the potential to improve the health and quality of life of diabetes patients.”
The Latest Bing News on:
- Feed has no items.
The Latest Google Headlines on:
The Latest Bing News on:
- Diabetes type 2 warning: 'Above average' urination is a warning sign of high blood sugaron January 16, 2021 at 2:34 pm
DIABETES type 2 is barely perceptible until high blood sugar levels start to encroach on bodily functions. When this happens, one of the first casualties is above average urination - do you experience ...
- Diabetes type 2 symptoms: The warning signs when you wake up in the morningon January 15, 2021 at 12:42 am
DIABETES type 2 does not announce itself with a thunderous force, rather, the symptoms are subtle. You may be met with a number of symptoms when you wake up in the morning.
- Metformin drug decreases mortality rate in COVID-19 patients with type 2 diabeteson January 14, 2021 at 10:30 pm
Use of the diabetes drug metformin -- before a diagnosis of COVID-19 -- is associated with a threefold decrease in mortality in COVID-19 patients with Type 2 diabetes, according to a racially diverse ...
- Metformin use reduces risk of death for patients with COVID-19 and diabetes, study findson January 14, 2021 at 2:25 pm
Use of the diabetes drug metformin -- before a diagnosis of COVID-19 -- is associated with a threefold decrease in mortality in COVID-19 patients with Type 2 diabetes, according to a new study.
- Metformin use reduces risk of death for patients with COVID-19 and diabeteson January 14, 2021 at 1:33 pm
Use of the diabetes drug metformin—before a diagnosis of COVID-19—is associated with a threefold decrease in mortality in COVID-19 patients with Type 2 diabetes, according to a racially diverse study ...
- Drug found to be safe and effective for treating patients with obesity and type 2 diabeteson January 13, 2021 at 5:17 pm
A new study confirms that treatment with Bimagrumab, an antibody that blocks activin type II receptors and stimulates skeletal muscle growth, is safe and effective for treating excess adiposity and ...
- Diabetes Then and Now: Taking Advantage of Modern Management Strategieson January 13, 2021 at 1:36 pm
And while she’s personally experienced advances in her own diabetes care over time, particularly with her switch to a continuous glucose monitor (CGM), the enormity of the change didn’t hit her until ...
- Diabetes Treatment And Prevention Market 2021 Leading Companies Outlook, Segments Insights, Competitive Landscape & Growth Prospectson January 13, 2021 at 10:15 am
BRICS Diabetes Treatment and Prevention Market report by Expert Analyst of MRFR. Provides industry players, segmentation ...
- Global Type-1 Diabetes Treatment Market Is Estimated to Register a CAGR of 7.9%. by 2025 | Research by MRFRon January 13, 2021 at 3:28 am
Diabetes refers to a category of metabolic diseases characterized by high blood sugar levels. Diabetes is caused ...
- Why Dr. Denise Faustman Isn’t Deterred by Skeptics of Her Type 1 Diabetes Cure Researchon January 12, 2021 at 11:39 am
Denise Faustman and her research on a low-cost diabetes cure are quite controversial — now she's working on COVID-19.